Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 06, 2019 | June 10, 2019 |
| ELI LILLY & CoLLY · Entity 2794 | President, Mfg. Operations | December 31, 2006 | February 12, 2007 |
| Oncorus, Inc.ONCR · Entity 112213 | Director | June 23, 2022 | June 24, 2022 |
| Outlook Therapeutics, Inc.ONS · Entity 608 | Director | October 26, 2017 | October 30, 2017 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | Director | June 08, 2018 | June 11, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 06, 2019 · Filed June 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,700 |
Reported balance
After 2019-06-06 transaction · row 1
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 13,700 · Balance 13,700 F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.23 · Expires 2029-06-06 | Direct | 20,100 |
Reported balance
After 2019-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-06 · Grant · Acquired 20,100 · Balance 20,100 F2: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
F2: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
ELI LILLY & Co
Report date December 31, 2006 · Filed February 12, 2007
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectAmy D. Canute Rev. Trust | 18,078 |
Reported balance
After 2006-06-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2006-06-13 · Gift · Disposed 1,293 · Balance 18,078 F1: Revocable Trust of which reporting person and his wife are trustee. |
| Common StockSEC Table I · non-derivative | Direct | 11,680 |
Reported balance
Holding disclosure · report date 2006-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 11,680 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,935 |
Reported balance
Holding disclosure · report date 2006-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,935 |
Filing footnotes · ownership attribution and instrument terms
F1: Revocable Trust of which reporting person and his wife are trustee.
Oncorus, Inc.
Report date June 23, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2032-06-23 | Direct | 12,500 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 12,500 · Balance 12,500 F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date.
Outlook Therapeutics, Inc.
Report date October 26, 2017 · Filed October 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-10-26 | Direct | 15,000 |
Reported balance
After 2017-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-26 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.
Protara Therapeutics, Inc.
Report date June 08, 2018 · Filed June 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2028-06-07 | Direct | 12,700 |
Reported balance
After 2018-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-08 · Grant · Acquired 12,700 · Balance 12,700 F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.38 · Expires 2025-03-03 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
IMMUNOMEDICS INC
Report date October 23, 2020 · Filed October 23, 2020
Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 1
1 source rowRow 1 · 2020-10-23 · Disposition to issuer · Disposed 13,516 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-23 · Disposition to issuer · Disposed 155,286 · Balance 0 F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-23 · Disposition to issuer · Disposed 3,718 · Balance 0 F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.
F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.
F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 29, 2005 Filed Feb 14, 2006 17:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 3 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 16, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/96 (right to buy) · Derivative | 2,000 | $0.00 Strike: $34.60 | $0.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · derivative · entry 9 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2006-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/95 (right to buy) · Derivative | 4,000 | $0.00 Strike: $23.41 | $0.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · derivative · entry 8 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2005-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 2,000 | $34.50 | $69,000.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · nonDerivative · entry 5 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,000 | $23.40 | $93,600.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · nonDerivative · entry 4 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 400 | $53.31 | $21,324.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · nonDerivative · entry 3 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753 Read SEC document |
| August 15, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 2,800 | $53.30 | $149,240.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · nonDerivative · entry 2 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,153 Read SEC document |
| August 10, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · nonDerivative · entry 6 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Amy D. Canute Rev. Trust Disclosed balance after: 13,948 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 10, 2005 Filed Aug 17, 2005 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-05-043153 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,953 Read SEC document |
| August 03, 2005 Filed Aug 5, 2005 18:38 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/96 (right to buy) · Derivative | 2,000 | $0.00 Strike: $34.60 | $0.00 |
DisclosureSEC source: 0001209191-05-041035 · doc4.xml · derivative · entry 7 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires 2006-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2005 Filed Aug 5, 2005 18:38 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/95 (right to buy) · Derivative | 4,000 | $0.00 Strike: $23.41 | $0.00 |
DisclosureSEC source: 0001209191-05-041035 · doc4.xml · derivative · entry 6 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 4,000 shares Expires 2005-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2005 Filed Aug 5, 2005 18:38 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 2,418 | $54.88 | $132,699.84 |
DisclosureSEC source: 0001209191-05-041035 · doc4.xml · nonDerivative · entry 4 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,044 Read SEC document |
| August 03, 2005 Filed Aug 5, 2005 18:38 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,491 | $54.88 | $81,826.08 |
DisclosureSEC source: 0001209191-05-041035 · doc4.xml · nonDerivative · entry 3 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,462 Read SEC document |
| August 03, 2005 Filed Aug 5, 2005 18:38 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,000 | $23.41 | $93,640.00 |
DisclosureSEC source: 0001209191-05-041035 · doc4.xml · nonDerivative · entry 2 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2005 Filed Aug 5, 2005 18:38 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 2,000 | $34.60 | $69,200.00 |
DisclosureSEC source: 0001209191-05-041035 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2005 Filed Aug 9, 2005 19:30 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/96 (right to buy) · Derivative | 4,000 | $0.00 Strike: $34.60 | $0.00 |
DisclosureSEC source: 0001209191-05-041590 · doc4a.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 4,000 shares Expires 2006-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The amendment is being filed to correct the number of beneficially owned shares reported as acquired on the original Form 4 when the shares were actually disposed of. F1 · derivative.underlying_shares: The amendment is being filed to correct the number of beneficially owned shares reported as acquired on the original Form 4 when the shares were actually disposed of. Read SEC document |
| August 03, 2005 Filed Aug 9, 2005 19:30 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/95 (right to buy) · Derivative | 8,000 | $0.00 Strike: $23.41 | $0.00 |
DisclosureSEC source: 0001209191-05-041590 · doc4a.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 8,000 shares Expires 2005-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The amendment is being filed to correct the number of beneficially owned shares reported as acquired on the original Form 4 when the shares were actually disposed of. Read SEC document |
| June 28, 2005 Filed Feb 14, 2006 17:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 6 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 7 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Amy D. Canute Rev. Trust Disclosed balance after: 14,480 F1 · ownership.direct: Revocable Trust of which reporting person and his wife are trustee. Read SEC document |
| June 23, 2005 Filed Feb 14, 2006 17:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 6 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Amy D. Canute Rev. Trust Disclosed balance after: 14,486 F1 · ownership.direct: Revocable Trust of which reporting person and his wife are trustee. Read SEC document |
| May 23, 2005 Filed Jul 21, 2005 20:59 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 926 | $58.90 | $54,541.40 |
DisclosureSEC source: 0001209191-05-038077 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,953 Read SEC document |
| May 23, 2005 Filed Feb 14, 2006 17:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 5 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Amy D. Canute Rev. Trust Disclosed balance after: 15,810 F1 · ownership.direct: Revocable Trust of which reporting person and his wife are trustee. Read SEC document |
| May 23, 2005 Filed Feb 14, 2006 17:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 2 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 06, 2005 Filed Feb 14, 2006 17:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 4 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Amy D. Canute Rev. Trust Disclosed balance after: 13,736 F1 · ownership.direct: Revocable Trust of which reporting person and his wife are trustee. Read SEC document |
| May 06, 2005 Filed Feb 14, 2006 17:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| February 11, 2005 Filed Feb 15, 2005 21:37 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantEmployee stock option (right to buy) · Derivative | 46,154 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-05-000055 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,154 Underlying: Common Stock · 46,154 shares Expires 2015-02-10 Read SEC document |
| January 14, 2005 Filed Jan 18, 2005 20:04 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,879 | $56.79 | $106,708.41 |
DisclosureSEC source: 0000059478-05-000023 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,879 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.